MX2021000291A - Composicion farmaceutica que comprende polipeptido. - Google Patents

Composicion farmaceutica que comprende polipeptido.

Info

Publication number
MX2021000291A
MX2021000291A MX2021000291A MX2021000291A MX2021000291A MX 2021000291 A MX2021000291 A MX 2021000291A MX 2021000291 A MX2021000291 A MX 2021000291A MX 2021000291 A MX2021000291 A MX 2021000291A MX 2021000291 A MX2021000291 A MX 2021000291A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
polypeptide
effects
nausea
vomiting
Prior art date
Application number
MX2021000291A
Other languages
English (en)
Inventor
Kang Choon Lee
Og Yi Park
Hyoung Tae An
Eun Ji Park
Jae Hee Shin
Sung Mook Lim
Original Assignee
D&D Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180083946A external-priority patent/KR101990075B1/ko
Priority claimed from KR1020190060513A external-priority patent/KR20200135618A/ko
Application filed by D&D Pharmatech Inc filed Critical D&D Pharmatech Inc
Publication of MX2021000291A publication Critical patent/MX2021000291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica que incluye un polipéptido, y más particularmente, a una composición farmacéutica para prevenir o tratar obesidad, diabetes o enfermedad de hígado graso no alcohólico. La composición farmacéutica es segura sin cualquiera de los efectos secundarios tal como vómito o náusea, y tiene efectos en reducir la ingesta de alimento, aumentar la secreción de insulina, suprimir el vaciado gástrico, promover la lipólisis y disminuir un nivel de triglicéridos.
MX2021000291A 2018-07-19 2019-07-19 Composicion farmaceutica que comprende polipeptido. MX2021000291A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180083946A KR101990075B1 (ko) 2018-07-19 2018-07-19 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR1020190060513A KR20200135618A (ko) 2019-05-23 2019-05-23 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
PCT/KR2019/008918 WO2020017916A1 (en) 2018-07-19 2019-07-19 Pharmaceutical composition comprising polypeptide

Publications (1)

Publication Number Publication Date
MX2021000291A true MX2021000291A (es) 2021-03-31

Family

ID=69164132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000291A MX2021000291A (es) 2018-07-19 2019-07-19 Composicion farmaceutica que comprende polipeptido.

Country Status (10)

Country Link
US (1) US20210317178A1 (es)
EP (1) EP3823659A4 (es)
JP (2) JP2021530533A (es)
CN (1) CN112912095A (es)
AU (1) AU2019308089A1 (es)
BR (1) BR112021000933A2 (es)
CA (1) CA3106852A1 (es)
IL (1) IL279707A (es)
MX (1) MX2021000291A (es)
WO (1) WO2020017916A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JO2976B1 (en) * 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
EP2721062B1 (en) * 2011-06-17 2018-11-14 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
ES2748158T3 (es) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
DK3322437T3 (da) * 2015-06-30 2024-03-25 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
JP2023144098A (ja) 2023-10-06
US20210317178A1 (en) 2021-10-14
BR112021000933A2 (pt) 2021-04-27
CN112912095A (zh) 2021-06-04
WO2020017916A1 (en) 2020-01-23
EP3823659A4 (en) 2022-06-22
EP3823659A1 (en) 2021-05-26
IL279707A (en) 2021-03-01
JP2021530533A (ja) 2021-11-11
CA3106852A1 (en) 2020-01-23
AU2019308089A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2022004041A (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos.
MX2018012686A (es) Composicion para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina.
PH12015501009B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
RU2014112223A (ru) Способ профилактики и/или лечения инсулинорезистентности
ATE486497T1 (de) Frittierfettzusammensetzung
JP2015522573A5 (es)
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2018006271A (es) Suplemento alimenticio y composicion para tratar sindrome metabolico.
RU2018138995A (ru) Способы индуцирования и пролонгирования насыщения, уменьшения объёма и поглощения пищи, контроля веса и стимулирования снижения веса, пищевая композиция
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
MX2022014291A (es) Composiciones para mejorar la biodisponibilidad de productos farmaceuticos, suplementos y sustancias ingeridas.
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
MX2016008102A (es) Composiciones y métodos para tratar la acumulacion de tejido graso.
WO2011136573A3 (ko) 비만 치료 및 항산화 활성을 갖는 효모 가수분해물
MX2021000291A (es) Composicion farmaceutica que comprende polipeptido.
EA201791173A1 (ru) Композиция, содержащая пентозу и полифенольное соединение
MX2017003217A (es) Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.
WO2016008642A3 (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
MX2021014371A (es) Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones.
WO2005097174A3 (en) Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
PH12020551900A1 (en) Novel compound exhibiting enteropeptidase inhibitory activity
CN106880649A (zh) 蚯蚓白砂糖汁地皮菜
CN105725095A (zh) 一种治疗高血压的食疗配方
TH11256A3 (th) สูตรอาหารเลี้ยงกุ้งกุลาดำที่ประกอบด้วยแคลเซียมคาร์บอเนต (Calcium Carbonate) และน้ำมัน
TH147853A (th) อนุพันธ์อ็อกซินทอโมดัลลินชนิดใหม่ และองค์ประกอบเภสัชกรรมสำหรับการรักษาภาวะอ้วนน้ำหนักมากเกินประกอบด้วยอนุพันธ์เดียวกัน